Vol. 2 No. 8 (2022)
Reimbursement Recommendations

Selinexor (Xpovio)

Published August 17, 2022

Key Messages

  • CADTH recommends that Xpovio should be reimbursed by public drug plans for the treatment of multiple myeloma if certain conditions are met.
  • Xpovio should only be covered to treat adult patients with multiple myeloma who have received at least 1 prior therapy.
  • Xpovio should only be reimbursed if prescribed by a specialist, given in combination with bortezomib and dexamethasone, and the cost of Xpovio is reduced.